Keros Therapeutics Stock Fundamentals
| KROS Stock | USD 11.58 0.11 0.96% |
Keros Therapeutics fundamentals help investors to digest information that contributes to Keros Therapeutics' financial success or failures. It also enables traders to predict the movement of Keros Stock. The fundamental analysis module provides a way to measure Keros Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Keros Therapeutics stock.
At this time, Keros Therapeutics' Net Interest Income is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 225.1 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 927.8 K in 2025. Keros | Select Account or Indicator |
Keros Therapeutics Company Return On Asset Analysis
Keros Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Keros Therapeutics Return On Asset | -0.27 |
Most of Keros Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Keros Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Keros Total Assets
Total Assets |
|
Based on the latest financial disclosure, Keros Therapeutics has a Return On Asset of -0.2673. This is 96.95% lower than that of the Biotechnology sector and 98.87% lower than that of the Health Care industry. The return on asset for all United States stocks is 90.93% higher than that of the company.
Keros Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Keros Therapeutics's current stock value. Our valuation model uses many indicators to compare Keros Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Keros Therapeutics competition to find correlations between indicators driving Keros Therapeutics's intrinsic value. More Info.Keros Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Keros Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Keros Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Keros Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Keros Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics of similar companies.Keros Therapeutics is currently under evaluation in return on asset category among its peers.
Keros Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Keros Therapeutics from analyzing Keros Therapeutics' financial statements. These drivers represent accounts that assess Keros Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Keros Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.1B | 1.4B | 1.2B | 1.2B | 592.6M | 661.9M | |
| Enterprise Value | 828.8M | 1.1B | 946.3M | 854.1M | 51.6M | 49.0M |
Keros Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Keros Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Keros Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Keros Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (17.51) % | ||||
| Current Valuation | (71.36 M) | ||||
| Shares Outstanding | 40.56 M | ||||
| Shares Owned By Insiders | 2.29 % | ||||
| Shares Owned By Institutions | 97.71 % | ||||
| Number Of Shares Shorted | 4.13 M | ||||
| Price To Book | 0.81 X | ||||
| Price To Sales | 132.31 X | ||||
| Revenue | 3.55 M | ||||
| Gross Profit | (14.74 M) | ||||
| EBITDA | (185.82 M) | ||||
| Net Income | (187.35 M) | ||||
| Cash And Equivalents | 215.62 M | ||||
| Cash Per Share | 8.37 X | ||||
| Total Debt | 18.86 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.39 X | ||||
| Book Value Per Share | 14.09 X | ||||
| Cash Flow From Operations | (160.87 M) | ||||
| Short Ratio | 3.86 X | ||||
| Earnings Per Share | (5.00) X | ||||
| Target Price | 33.64 | ||||
| Number Of Employees | 169 | ||||
| Beta | 1.4 | ||||
| Market Capitalization | 469.71 M | ||||
| Total Asset | 615.89 M | ||||
| Retained Earnings | (568.78 M) | ||||
| Working Capital | 561.44 M | ||||
| Current Asset | 11.95 M | ||||
| Current Liabilities | 5.72 M | ||||
| Net Asset | 615.89 M |
About Keros Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Keros Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 19.8 M | 20.8 M | |
| Total Revenue | 3.5 M | 3.4 M | |
| Cost Of Revenue | 733.5 K | 696.8 K | |
| Stock Based Compensation To Revenue | 9.82 | 9.33 | |
| Sales General And Administrative To Revenue | 11.48 | 10.91 | |
| Research And Ddevelopement To Revenue | 48.91 | 46.46 | |
| Capex To Revenue | 0.54 | 0.52 | |
| Revenue Per Share | 0.09 | 0.09 | |
| Ebit Per Revenue | (59.39) | (62.36) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.